Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. “We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. “The initiation of our Phase 1 study of PRO-XTEN™ dual-masked VIR-5525 positions us to potentia